COVID-19 Should Force ‘Soul Searching’ Over Fragmented US Clinical Trials System, Woodcock Says

 
• By Sue Sutter

Among hundreds of trials underway on potential therapeutics, only about 6% of study arms are expected to yield actionable data because most are nonrandomized, underpowered or underenrolled, Operation Warp Speed’s Janet Woodcock says, renewing her pitch for adoption of master protocols and other approaches to streamline studies and improve efficiency.

Landscape
After COVID, there is going to be some soul searching for a better way to collect clinical evidence. • Source: Shutterstock

More from Clinical Trials

More from R&D